| Polymorphs, salts, and cocrystals: what’s in a name? S Aitipamula, R Banerjee, AK Bansal, K Biradha, ML Cheney, ... Crystal growth & design 12 (5), 2147-2152, 2012 | 1056 | 2012 |
| Pharmaceutical cocrystals: along the path to improved medicines NK Duggirala, ML Perry, Ö Almarsson, MJ Zaworotko Chemical communications 52 (4), 640-655, 2016 | 929 | 2016 |
| Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics ML Cheney, DR Weyna, N Shan, M Hanna, L Wojtas, MJ Zaworotko Journal of pharmaceutical sciences 100 (6), 2172-2181, 2011 | 273 | 2011 |
| Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine ML Cheney, N Shan, ER Healey, M Hanna, L Wojtas, MJ Zaworotko, ... Crystal Growth & Design 10 (1), 394-405, 2010 | 273 | 2010 |
| Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study ML Cheney, DR Weyna, N Shan, M Hanna, L Wojtas, MJ Zaworotko Crystal growth & design 10 (10), 4401-4413, 2010 | 148 | 2010 |
| Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics N Shan, ML Perry, DR Weyna, MJ Zaworotko Expert opinion on drug metabolism & toxicology 10 (9), 1255-1271, 2014 | 144 | 2014 |
| Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation DR Weyna, ML Cheney, N Shan, M Hanna, MJ Zaworotko, V Sava, ... Molecular pharmaceutics 9 (7), 2094-2102, 2012 | 144 | 2012 |
| Crystallization method and bioavailability M Hanna, N Shan, M Cheney, D Weyna, RK Houck US Patent 8,399,023, 2013 | 117 | 2013 |
| Oral forms of a phosphonic acid derivative M Hanna, N Shan, M Cheney, D Weyna US Patent 8,980,868, 2015 | 109 | 2015 |
| In vivo studies of crystalline forms of meloxicam M Hanna, N Shan, ML Cheney, DR Weyna US Patent 8,124,603, 2012 | 98 | 2012 |
| The role of cocrystals in solid-state synthesis: cocrystal-controlled solid-state synthesis of imides ML Cheney, GJ McManus, JA Perman, Z Wang, MJ Zaworotko Crystal growth & design 7 (4), 616-617, 2007 | 96 | 2007 |
| Crystallization method and bioavailability M Hanna, N Shan, ML Cheney, DR Weyna, RK Houck US Patent 8,933,057, 2015 | 89 | 2015 |
| Crystallization method and bioavailability M Hanna, N Shan, ML Cheney, DR Weyna, R Houck US Patent 9,169,279, 2015 | 85 | 2015 |
| Hydrogen bond hierarchy: persistent phenol··· chloride hydrogen bonds in the presence of carboxylic acid moieties NK Duggirala, GPF Wood, A Fischer, Ł Wojtas, ML Perry, MJ Zaworotko Crystal Growth & Design 15 (9), 4341-4354, 2015 | 61 | 2015 |
| Towards an understanding of the propensity for crystalline hydrate formation by molecular compounds A Bajpai, HS Scott, T Pham, KJ Chen, B Space, M Lusi, ML Perry, ... IUCrJ 3 (6), 430-439, 2016 | 50 | 2016 |
| Improving biopharmaceutical properties of vinpocetine through cocrystallization S Golob, M Perry, M Lusi, MR Chierotti, I Grabnar, L Lassiani, D Voinovich, ... Journal of pharmaceutical sciences 105 (12), 3626-3633, 2016 | 42 | 2016 |
| Crystal engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs DR Weyna, ML Cheney, N Shan, M Hanna, Ł Wojtas, MJ Zaworotko CrystEngComm 14 (7), 2377-2380, 2012 | 40 | 2012 |
| Cocrystal Controlled Solid-State Synthesis. A Green Chemistry Experiment for Undergraduate Organic Chemistry ML Cheney, MJ Zaworotko, S Beaton, RD Singer Journal of chemical education 85 (12), 1649, 2008 | 34 | 2008 |
| Cocrystal Polymorphs and Solvates of the Anti-Trypanosoma cruzi Drug Benznidazole with Improved Dissolution Performance BP Bezerra, D Pogoda, ML Perry, LMT Vidal, MJ Zaworotko, AP Ayala Crystal Growth & Design 20 (7), 4707-4718, 2020 | 23 | 2020 |
| Chloral hydrate polymorphs and cocrystal revisited: solving two pharmaceutical cold cases D O’Nolan, ML Perry, MJ Zaworotko Crystal Growth & Design 16 (4), 2211-2217, 2016 | 22 | 2016 |
